SCHEMBL8367941

SCHEMBL8367941

O=C(O)C1CN(c2ccc(F)cc2)c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
NOTUM Q6P988 3/20 0.42
KCNH2 Q12809 1/20 0.42
TSHR P16473 3/20 0.41
USP2 O75604 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 2/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
FADS1 O60427 1/20 0.40
CACNA1G O43497 1/20 0.39
CACNA1H O95180 1/20 0.39
CACNA1I Q9P0X4 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
RECQL P46063 1/20 0.38
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8374944 0.85 LMNA (0.42) MAPTNOTUMTSHRNPSR1ALDH1A1
SCHEMBL27859225 0.85 KCNH2 (0.40) MAPTNOTUMKCNH2TSHRUSP2
SCHEMBL31530864 0.74 NOTUM (0.45) MAPTNOTUMTSHRALDH1A1FADS1
SCHEMBL31378007 0.71 NOTUM (0.51) MAPTNOTUMALDH1A1CACNA1GTDP1
SCHEMBL30099061 0.71 NOTUM (0.47) MAPTNOTUMALDH1A1
SCHEMBL8374942 0.71 NOTUM (0.51) MAPTNOTUMTSHRUSP2ALDH1A1
SCHEMBL30099079 0.69 NOTUM (0.41) NOTUMALDH1A1CACNA1GCACNA1HCACNA1I
SCHEMBL21938738 0.69 NOTUM (0.41) MAPTNOTUMTSHRALDH1A1SMN1; SMN2
SCHEMBL15834250 0.69 ROCK1 (0.68)
SCHEMBL20080338 0.69 NOTUM (0.34) MAPTNOTUMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324012-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324012-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA MAPT 4519/4885NOTUM 173/4885KCNH2 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.